Even though data presented this month show neratinib failed to graduate from I-SPY 2 in HER2-negative breast cancer, Puma Biotechnology Inc. thinks the compound will have a role in the setting.

According to the company, part of the reason neratinib didn't clear the hurdle is that treatment was stopped in all neratinib arms after the compound graduated in a different population: HER2-positive/hormone receptor-negative neoadjuvant breast cancer.